

Mouse Anti-MAGE1 [MA454]: MC0836, MC0836RTU7

Intended Use: For Research Use Only

Description: Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes. Never expressed in kidney tumors, leukemias and lymphomas. May be involved in transcriptional regulation through interaction with SNW1 and recruiting histone deacetylase HDAC1. May inhibit notch intracellular domain (NICD) transactivation. May play a role in embryonal development and tumor transformation or aspects of tumor progression. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes.

Specifications


Clone: MA454
 Source: Mouse
 Isotype: IgG1k
 Reactivity: Human, rat, dog
 Localization: Cytoplasm
 Formulation: Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN₃)
 Storage: Store at 2°- 8°C
 Applications: IHC, Flow Cyt.
 Package:

Description	Catalog No.	Size
MAGE1 Concentrated	MC0836	1 ml
MAGE1 Prediluted	MC0836RTU7	7 ml

IHC Procedure*

Positive Control Tissue: Melanomas, gliomas, neuroblastoma, NSCLC, breast, gastric, colorectal, ovarian, RCC
 Concentrated Dilution: 50-200
 Pretreatment: Citra pH6.0, or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human testis stained with anti-MAGE1 using DAB

References:

1. The prevalence and expression pattern of melanoma-associated antigen 1 in esophageal squamous cell carcinoma: a historical cohort study. Anvari K et al. Electron Physician, 2017.
2. MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases. Hansel DE et al. Int J Gastrointest Cancer, 2003.
3. The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following different administration routes. Ge W et al. Oncol Rep. 2009.